Exact Sciences stock is trading -13.34% below its average target price of $82.1 after marking a 2.1% during today's morning session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $54.0 to $100.0 per share.
Exact Sciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.8%. The stock's short ratio is 3.77. The company's insiders own 0.9% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 95.4%. In conclusion, we believe there is mixed market sentiment regarding Exact Sciences.
Institutions Invested in Exact Sciences
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | FMR, LLC | 10% | 18,650,381 | $1,326,974,636 |
| 2025-09-30 | Vanguard Group Inc | 9% | 17,808,477 | $1,267,073,165 |
| 2025-09-30 | Capital World Investors | 9% | 16,140,861 | $1,148,422,284 |
| 2025-09-30 | Blackrock Inc. | 6% | 10,562,161 | $751,497,771 |
| 2025-09-30 | Wellington Management Group, LLP | 3% | 5,325,981 | $378,943,556 |
| 2025-09-30 | State Street Corporation | 3% | 5,195,281 | $369,644,251 |
| 2025-09-30 | Ameriprise Financial, Inc. | 2% | 4,493,085 | $319,683,004 |
| 2025-09-30 | Citadel Advisors Llc | 2% | 3,941,587 | $280,443,921 |
| 2025-09-30 | Massachusetts Financial Services Co. | 2% | 3,909,501 | $278,161,002 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 3,311,827 | $235,636,496 |
